FDA Reports Two Deaths Tied to Bootleg Weight-Loss Drug

U.S. health authorities are investigating whether a bootleg version of an experimental weight-loss drug caused two deaths, according to adverse event reports reviewed by CBS News. The reports, obtained through the Freedom of Information Act, link the deaths to products marketed as retatrutide — an unapproved Eli Lilly drug that has not received clearance from the Food and Drug Administration. While the reports do not establish that the drugs caused the deaths, they mark the first public U.S. accounts alleging that unauthorized retatrutide use played a role in a patient’s death, and they underscore the hazards of a rapidly expanding gray market for GLP-1-style medications.

What the Reports Say

The FDA’s Adverse Event Reporting System received the two reports in recent months. In the first case, documented in July 2026, a healthcare professional told the agency that a 41-year-old woman with obesity went into cardiac arrest and died after multiple resuscitation attempts failed. The report lists retatrutide as a “suspect product,” noting that the woman obtained it “from an unreliable source.” She was reportedly drinking kava at the time of the emergency. According to the redacted FDA case documents, the episode was not connected to a formal clinical trial.

In the second case, reported in September 2026, a 49-year-old patient died after a licensed nurse “convinced” her to buy retatrutide from an online peptide vendor, according to the second FDA case file. The patient experienced severe dehydration, malnutrition, and cardiac arrest. The report states the nurse “provided her the link and sold her vials and provided recommended dosages.” An image included in the filing shows a vial labeled “AlphaLabs” bearing a website that offers peptides for “research use only.”

CBS News could not independently verify the contents of the reports, which the FDA redacted to protect patient identities. The agency declined to say whether it had verified the information, stating only that it reviews adverse event reports and gathers additional information when needed.

A Growing and Unregulated Market

The cases arrive amid a sharp rise in reported harms. America’s Poison Centers logged 862 retatrutide exposures in the three months ending September 2026 — up from 460 in the prior quarter and 249 in the first three months of the year, a steady and accelerating increase.

Retatrutide is a “triple agonist” that targets GLP-1, GIP, and glucagon receptors. Published Phase 3 trial results in The Lancet show it produces even greater weight loss than the most effective obesity drugs currently on the market, such as Zepbound and Wegovy, fueling widespread anticipation of a blockbuster product. Eli Lilly has said it plans to seek FDA approval, with some reporting pointing to the first quarter of 2027.

Because the drug is not yet approved, any commercial sale of it is illegal under federal law (21 U.S.C. § 355). Yet vendors have sold imitation versions online “at a scale with no modern precedent,” according to reporting compiled by RealClearHealth. CBS News has previously found the compound widely available in health spas, on wellness websites, and even in convenience stores, with dozens of medical professionals openly promoting access.

Lilly’s Legal Offensive

Eli Lilly has moved aggressively against the black market. In August 2026, the company sued six companies over illegal retatrutide sales, as Quartz reported. Several defendants labeled the product “research use only” while marketing it for human injection, and three of them pulled listings offline within days. The legal fight, detailed by Highrock, reflects Lilly’s concern that adverse reactions to bootleg versions will “poison the well for the future of retatrutide medicines.”

In a statement, the company said the reported deaths “make clear the two individuals were taking black-market retatrutide.” It said testing had found suspect products “with too much, too little, or the wrong active ingredient,” along with contaminants that “can put patients at serious risk.”

A parallel controversy has surrounded the certification body LegitScript, whose seal some sellers used to lend an air of legitimacy. Reporting indicates that more than 80 retatrutide sellers displayed the LegitScript seal, and that the certification was used to facilitate advertising pipelines — a finding examined in a CBS News investigation into how unapproved products reached consumers.

Expert Concern

Drug-safety experts say the episode points to a broader lapse in oversight. “It is concerning because of the breakdown of our drug-approval process in the United States of America,” said Pieter Cohen, an associate professor at Harvard Medical School. He urged the FDA to obtain and analyze the actual substances involved. “The FDA should do whatever it possibly could do to get their hands on the actual drug that was injected by both of these patients, and they should get that analyzed,” Cohen said. “If the FDA is not aggressively investigating these cases, that’s deeply concerning.”

The attorney for Alpha Labs owner Joseph Samara, Sinead Killeen, extended sympathies to the family of the individual described in the second report. She added that “a licensed healthcare professional should never recommend research-use-only products to a patient, provide dosing instructions for them, administer them, or sell them.” When reached initially, Samara denied the company sold retatrutide.

Analysis: A Regulatory Gap Widens

The retatrutide cases illustrate a recurring pattern in the GLP-1 era: intense consumer demand outpaces regulatory approval, and unapproved supply chains rush to fill the void. Retatrutide is not a fringe compound — it is a closely watched candidate that Drugs.com notes remains investigational — yet its notoriety has made it a magnet for counterfeiters.

The FDA’s authority over unapproved drug sales is longstanding, as the agency’s Adverse Event Reporting System framework and federal law make clear. The harder problem is enforcement: an online ecosystem of peptide vendors and social media promoters is diffuse and difficult to police. The involvement of a licensed nurse in the second case — someone entrusted with patient welfare — suggests that the demand is being met not only by shadowy sellers but by professionals who lend the market credibility.

Crucially, causation remains unproven. Adverse event reports record a possible link, not a confirmed one, and the FDA has not said how thoroughly it has investigated. Both patients also had complicating factors, and identities were redacted. Still, the trend in poison-center exposures is difficult to dismiss as coincidence.

What’s Next

Several questions remain unresolved. Whether the FDA is actively analyzing the drugs that were injected is unknown. The identity of the nurse and the specific vendor in the second case have not been disclosed. And Alpha Labs’ attorney said the company has not been contacted by the FDA. As retatrutide moves closer to a potential approval decision, the gap between its medical promise and its illicit availability is likely to widen — unless regulators can close it first.